Aridis Pharmaceuticals Announces a Monoclonal Antibody Cocktail That Holds Effectiveness Against the Omicron variant

Dec 21, 2021 By MarketDepth

Biotechnology Business Headlines Healthcare Investing What's Hot

Covid masks

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped more than 30% after the Company announced that its fully human monoclonal antibody (mAb) cocktail AR-701 is broadly reactive against the Omicron and other COVID-19 (SARS-CoV-2) variants, SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome Coronavirus), and seasonal (‘common cold’) human coronaviruses.

Viral Infusion

According to the Company AR-701 is a cocktail of two fully human immunoglobulin G1 (IgG1) mAbs discovered from screening the antibody secreting B-cells of convalescent SARS-CoV-2 infected (COVID-19) patients. AR-701 consists of AR-703 and AR-720 mAbs, each neutralizes coronaviruses using distinct mechanisms of action, namely inhibition of viral fusion and entry into human cells (AR-703) and blockage of viral binding to the human ‘ACE2’ receptor (AR-720).

“Omicron has rendered current COVID-19 vaccines and monoclonal antibodies substantially less effective, and likely future COVID 19 variants will arise that continue this trend. AR-701 is the result of our successful search for a mAb therapy that is directed against a conserved region of the virus that would be less vulnerable to mutations and new variants such as Omicron. Our laboratory data suggest that AR-701 has the potential to be a future-proof COVID-19 therapy that can protect against SARS-CoV-2, SARS, or MERS pandemics,” continued Dr. Truong. “To our knowledge AR-701 is the only COVID-19 therapy that targets two distinct viral mechanisms of action, making it much harder for the virus to generate resistance, and exhibits an unmatched combination of broad reactivity and high efficacy.”

Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals